KDS2010

• CAT Number: I030028
• CAS Number: 1894207-44-3
• Molecular Formula: C18H21F3N2O4S
• Molecular Weight: 418.43
• Purity: 98%
• Synonyms: KDS-2010; KDS 2010; KDS2010
• Target: Monoamine Oxidase
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (S)-2-(((4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)amino)propanamide Mesylate
• InChI: InChI=1S/C17H17F3N2O.CH4O3S/c1-11(16(21)23)22-10-12-2-4-13(5-3-12)14-6-8-15(9-7-14)17(18,19)20;1-5(2,3)4/h2-9,11,22H,10H2,1H3,(H2,21,23);1H3,(H,2,3,4)/t11-;/m0./s1
• InChIKey: AXIUZWFYRNNIFL-MERQFXBCSA-N
• SMILES: C[C@H](NCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(N)=O.OS(=O)(C)=O

KDS2010 (Cat No.: I030028) is a highly selective, reversible inhibitor of monoamine oxidase-B (MAO-B), developed for the treatment of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease. Unlike irreversible MAO-B inhibitors, KDS2010 offers improved safety and reduced side effects by preserving enzyme function over time. It reduces oxidative stress and neuroinflammation by inhibiting dopamine breakdown and hydrogen peroxide production. In preclinical studies, KDS2010 demonstrated potent neuroprotective effects and good blood-brain barrier penetration, making it a promising candidate for disease-modifying therapies in CNS disorders.

Reference

1: Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar. PubMed PMID: 30906861; PubMed Central PMCID: PMC6426469.